Can I read Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity on EtoBox?

Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity by Maryam Nabati; Ghasem Janbabai; Saideh Baghyari; Khadige Esmaili; Jamshid Yazdani is a Medicine article available to read on EtoBox.

What is Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity about?

## Purpose: Anthracyclines (ANTs) are a class of active antineoplastic agents with topoisomerase-interacting activity that are considered the most active agents for the treatment of breast cancer. We investigated the efficacy of carvedilol in the inhibition of ANT-induced cardiotoxicity. ## Methods: In this randomized, single-blind, placebo-controlled study, 91 women with recently diagnosed breast cancer undergoing ANT therapy were randomly assigned to groups treated with either carvedilol (n = 46) or placebo (n = 45). Echocardiography was performed before and at 6 months after randomization, and absolute changes in the mean left ventricular ejection fraction, left ventricular end diastolic volume, and left ventricular end systolic volume were determined. Furthermore, the percentage change in the left atrial (LA) diameter and other variables of left ventricular (LV) diastolic function, such as transmitral Doppler parameters, including early (E wave) and late (A wave) diastolic velocities, E/A ratio and E wave deceleration time, pulmonary venous Doppler signals, including forward systolic (S wave) and diastolic (D wave) velocities into LA, late diastolic atrial reversal velocity, an

Who reads Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity?

Author

Maryam Nabati; Ghasem Janbabai; Saideh Baghyari; Khadige Esmaili; Jamshid Yazdani

Publisher

Ovid Technologies (Wolters Kluwer Health)

Published

2017

Language

EN

Field

Medicine (Health Sciences)